FDA approves first biosimilar to Neulasta to help reduce the risk of infection during cancer treatment
FDA approves Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim) to decrease the chance of infection as suggested by febrile neutropenia in patients with non-myeloid cancer.
Source: Food and Drug Administration - Category: American Health Source Type: news
More News: American Health | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Neulasta